Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...
2023-12-26 13:19:21 ET More on AbCellera Biologics, Absci, etc. Exscientia Looks Promising In AI-Driven Drug Development AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platf...
2023-12-26 07:02:44 ET More on BioNTech, Moderna, etc. BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Pfizer: Buy The Panic Pfizer Is Not Cheap, And The 5.7% Yield Is Not As Safe As You Might Think Citi puts Pfizer on catalyst watch afte...
2023-12-23 04:18:53 ET Summary AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth potential. GSK's current financials, product la...
2023-12-20 12:00:32 ET Summary Liquidia Corporation is worth at least $15 in a win. Roivant Sciences is worth at least $12 per share. Burford Capital Limited is worth at least $20 per share. Value & Event Driven Investing I recently spoke for a half an hour a...
2023-12-20 09:00:00 ET In late November, Roche 's (OTC: RHHBY) subsidiary Genentech and the chipmaker Nvidia (NASDAQ: NVDA) agreed to collaborate on developing new medicines using artificial intelligence (AI) over the next few years. While the pair didn't announce the financ...
2023-12-19 13:13:17 ET Summary TG Therapeutics, Inc. stock has gone up a lot due to a Q3 revenue beat. However, look closely at the Q3 numbers, and you can see Briumvi wasn't responsible for the revenue beat. Briumvi hasn't done as well as it should have. My TG The...
– If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure – – Interim analysis results from first-of-its-kind Phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, m...
Roche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports Canada NewsWire Healthcare professionals greatly value navify Tumor Board for improving tumour board meeting experiences, offering a holistic view of data, facili...
2023-12-15 14:30:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company’s making these strides have incredible results to show...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...